In his editorial comment for the Fall 2026 issue of DDW, Editor Reece Armstrong discusses innovation, investment, and how these come together in the Drug Discovery Innovators & Investors (DDII) event series. In my time with DDW, I’ve learned first-hand about the challenges drug discovery and development… Read More
In June 2026, China’s National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen’s Claudin18.2 CAR-T, for advanced gastric cancer. It became the world’s first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese… Read More
Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every… Read More
Dr Tim Meyer, Research Group Leader Pharmaceutical Biotechnology at University Medical Center Göttingen, explains why the next generation of scientists must be trained differently for the lab. Academic life science research has traditionally been optimised for novelty. Students and early-career researchers are trained to design elegant proof-of-concept experiments, execute them… Read More
Now that this industry is seriously looking to advanced automation to reinvent the work it does, the data transformation imperative has soared back up the strategic agenda, says Ian Crone, ArisGlobal’s VP Europe & APAC Regulatory Solutions. Here, he reports on an impassioned panel debate that took place as part of the Life Science AI Exchange Podcast last year. The panel included subject… Read More
For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity… Read More
The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in US drug pricing and tariffs, led to spending dips and nervousness throughout the sector. SLAS2026 is a key point in the… Read More
Fred Ramsdell is Founder and Advisor, Sonoma Biotherapeutics and one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). He shares his career highlights with Diana Turner. DT: Can you tell us what you’re working on at the moment or your most recent… Read More
The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients. Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per… Read More
Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner. DT: What… Read More
For the drug discovery, and wider pharmaceutical industry, the year of 2025 can be characterised by the words turmoil and uncertainty. The second coming of President Trump brought with it a flurry of executive orders, tariffs and global bargaining that placed the US in a position… Read More
DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical… Read More
With the news that RFK Jr – America’s Secretary of Health and Human Services – has cancelled around $500 million in funding for mRNA vaccines research, the question arises of how far political opinion can sway both medical research and society’s trust in science. The decision by… Read More
Diana Turner caught up with Graham Hatfull, Eberly Family Professor of Biotechnology at the University of Pittsburgh, following his election to the Fellowship of the Royal Society. DT: Can you tell us what you do and what you’re working on at the moment? GH: My lab studies bacteriophages (phages),… Read More
Stephen Ralston, EVP Market Access and Health Economics Outcomes Research (HEOR) at Coronado Research, speaks to Lu Rahman about the latest trends in market access. LR: What is changing in the market access industry? SR: Market access is a vibrant industry that has evolved significantly over the past two decades,… Read More
Both online and in the DDW quarterly magazine, DDW editors interview industry researchers to shine a spotlight on their work in a feature called Meet the Researcher. A question often included is: If you could make everyone read one book, article or academic paper, what would it be and… Read More
